CoChat

A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia

Open access

Published version of a preprint

The DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.

Abstract

Background: New therapies are urgently needed for Alzheimer’s disease (AD). Sodium oligomannate (GV-971) is a marine-derived oligosaccharide with a novel proposed mechanism of action. The first phase 3 clinical trial of GV-971 has been completed in China. Methods: We conducted a phase 3, double-blind, placebo-controlled trial in participants with mild-to-moderate AD to assess GV-971 efficacy and safety. Participants were randomized to placebo or GV-971 (900 mg) for 36 weeks. The primary outcome was the drug-placebo difference in change from baseline on the 12-item cognitive subscale of the Alzheimer’s Disease Assessment Scale (ADAS-cog12). Secondary endpoints were drug-placebo differences on the Clinician’s Interview-Based Impression of Change with caregiver input (CIBIC+), Alzheimer’s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scale, and Neuropsychiatric Inventory (NPI). Safety and tolerability were monitored. Results: A total of 818 participants were randomized: 408 to GV-971 and 410 to placebo. A significant drug-placebo difference on the ADAS-Cog12 favoring GV-971 was present at each measurement time point, measurable at the week 4 visit and continuing throughout the trial. The difference between the groups in change from baseline was − 2.15 points (95% confidence interval, − 3.07 to − 1.23; p < 0.0001; effect size 0.531) after 36 weeks of treatment. Treatment-emergent adverse event incidence was comparable between active treatment and placebo (73.9%, 75.4%). Two deaths determined to be unrelated to drug effects occurred in the GV-971 group. Conclusions: GV-971 demonstrated significant efficacy in improving cognition with sustained improvement across all observation periods of a 36-week trial. GV-971 was safe and well-tolerated. Trial registration: ClinicalTrials.gov, NCT0229391 5. Registered on November 19, 2014

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13195-021-00795-7

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Enrollment, randomization, and completion. *Not treated n = 1, in GV-971 group
Fig. 1 Enrollment, randomization, and completion. *Not treated n = 1, in GV-971 groupCC BY · PubMed Central
Fig. 2 Mean ADAS-Cog12 score change from baseline at weeks 4, 12, 24, and 36 (observed value). The mean change from baseline to week 36 on the ADAS-Cog12 (with scores ranging from 0 to 75 and higher scores indicating greater impairment) by full analysis set was showed. Error bars represent standard errors (SE). p values are obtained from the Wilcoxon rank sum tests
Fig. 2 Mean ADAS-Cog12 score change from baseline at weeks 4, 12, 24, and 36 (observed value). The mean change from baseline to week 36 on the ADAS-Cog12 (with scores ranging from 0 to 75 and higher scores indicating greater impairment) by full analysis set was showed. Error bars represent standard errors (SE). p values are obtained from the Wilcoxon rank sum testsCC BY · PubMed Central
Fig. 3 Secondary outcome of CIBIC+ at week 36. p value is obtained from a stratified Cochran-Mantel-Haenszel (CMH) test, including stratification factors of MMSE at baseline, education level, and age group
Fig. 3 Secondary outcome of CIBIC+ at week 36. p value is obtained from a stratified Cochran-Mantel-Haenszel (CMH) test, including stratification factors of MMSE at baseline, education level, and age groupCC BY · PubMed Central
Fig. 4 Analyses for the change in primary and secondary outcomes from baseline to week 36. *The direction of the ADCS-ADL change scores was reversed for consistency with the other outcomes
Fig. 4 Analyses for the change in primary and secondary outcomes from baseline to week 36. *The direction of the ADCS-ADL change scores was reversed for consistency with the other outcomesCC BY · PubMed Central
Fig. 5 Mean ADAS-Cog12 score change from baseline at weeks 4, 12, 24, and 36 (observed value) on the ADAS-Cog12 by the MMSE subgroup. Error bars represent standard errors (SE). p values are obtained from the Wilcoxon rank sum tests
Fig. 5 Mean ADAS-Cog12 score change from baseline at weeks 4, 12, 24, and 36 (observed value) on the ADAS-Cog12 by the MMSE subgroup. Error bars represent standard errors (SE). p values are obtained from the Wilcoxon rank sum testsCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 45 references

Research works printed but not linked: 1

  1. Reisberg B. FS: Clinician’s interview-based impression of change-plus; in Kelly C, Newton-Howes G (eds): guide to assessment scales in dementia. London: Science Press; 1994.

Cited by

See all 226

Metadata

Authors
Xiao, S., Chan, P., Wang, T., Hong, Z., Wang, S., Kuang, W., He, J., Pan, X., Zhou, Y., Ji, Y., Wang, L., Cheng, Y., Peng, Y., Ye, Q., Wang, X., Wu, Y., Qu, Q., Chen, S., Li, S., Chen, W., Xu, J., Peng, D., Zhao, Z., Li, Y., Zhang, J., Du, Y., Chen, W., Fan, D., Yan, Y., Liu, X., Zhang, W., Luo, B., Wu, W., Shen, L., Liu, C., Mao, P., Wang, Q., Zhao, Q., Guo, Q., Zhou, Y., Li, Y., Jiang, L., Ren, W., Ouyang, Y., Wang, Y., Liu, S., Jia, J., Zhang, N., Liu, Z., He, R., Feng, T., Lu, W., Tang, H., Gao, P., Zhang, Y., Chen, L., Wang, L., Yin, Y., Xu, Q., Xiao, J., Cong, L., Cheng, X., Zhang, H., Gao, D., Xia, M., Lian, T., Peng, G., Zhang, X., Jiao, B., Hu, H., Chen, X., Guan, Y., Cui, R., Huang, Q., Xin, X., Chen, H., Ding, Y., Zhang, J., Feng, T., Cantillon, M., Chen, K., Cummings, J. L., Ding, J., Geng, M., & Zhang, Z.
Affiliations
  • Shanghai Jiao Tong University (CN)
  • Capital Medical University (CN)
  • Fudan University (CN)
  • Qilu Hospital of Shandong University (CN)
  • West China Hospital of Sichuan University (CN)
  • First Affiliated Hospital of Wenzhou Medical University (CN)
  • Guangzhou First People's Hospital (CN)
  • Nankai University (CN)
  • Tianjin Medical University General Hospital (CN)
  • Sun Yat-sen University (CN)
  • Union Hospital (CN)
  • First Affiliated Hospital of Xi'an Jiaotong University (CN)
  • Beijing Hospital (CN)
  • Sir Run Run Shaw Hospital (CN)
  • Northern Jiangsu People's Hospital (CN)
  • China-Japan Friendship Hospital (CN)
  • Shanghai Changzheng Hospital (CN)
  • Zhongnan Hospital of Wuhan University (CN)
  • Shandong University (CN)
  • Peking University Third Hospital (CN)
  • The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
  • First Affiliated Hospital Zhejiang University (CN)
  • Tongji University (CN)
  • Xiangya Hospital Central South University (CN)
  • Peking Union Medical College Hospital (CN)
  • Chinese PLA General Hospital (CN)
  • Second Affiliated Hospital of Soochow University (CN)
  • Banner Alzheimer’s Institute (US)
  • University of Nevada, Las Vegas (US)
  • Chinese Academy of Sciences (CN)
Corresponding author
  • Xiao, Shifu
  • Geng, Meiyu
  • Zhang, Zhenxin
Venue
Alzheimer's Research & Therapy
Published
2021-03-17
Volume
13
Issue
1
Pages
62-62
ISSN
1758-9193 (ISSN-L)
OpenAlex
W3159386017
Cited by
224
References
46
Citations by year
2026: 41 · 2025: 32 · 2024: 39 · 2023: 48 · 2022: 39 · 2021: 25
FWCI
23.93
Type
journal article
Language
en
Open access
Licence
Locations
  • Alzheimer s Research & Therapy (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Science and Technology Major Project for Investigational New Drugs (2011ZX09101-003-01, 2015ZX09101003, 2018ZX09711002-015)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
Alzheimer's disease, mild to moderate dementia, cognitive function, activities of daily living, neuropsychiatric symptoms, drug safety and tolerability
MeSH terms
Activities of Daily Living, Alzheimer Disease, China, Cholinesterase Inhibitors, Double-Blind Method, Pharmaceutical Preparations, Humans, Mannose, Oligosaccharides, Sodium, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia. https://app.cochat.ai/papers/10.1186/s13195-021-00795-7
The paper
Xiao, S., Chan, P., Wang, T., Hong, Z., Wang, S., Kuang, W., He, J., Pan, X., Zhou, Y., Ji, Y., Wang, L., Cheng, Y., Peng, Y., Ye, Q., Wang, X., Wu, Y., Qu, Q., Chen, S., Li, S., . . . Zhang, Z. (2021). A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia. Alzheimer's Research & Therapy. https://doi.org/10.1186/s13195-021-00795-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.